Search Result
Results for "
LTD
" in MedChemExpress (MCE) Product Catalog:
6
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-P2259
-
|
|
iGluR
|
Neurological Disease
|
|
TAT-GluA2 3Y, an interference peptide, blocks long-term depression (LTD) at glutamatergic synapses by disrupting the endocytosis of AMPAR. TAT-GluA2 3Y can alleviate Pentobarbital-induced spatial memory deficits and synaptic depression .
|
-
-
- HY-156978
-
|
Wy-48252
|
Leukotriene Receptor
|
Others
|
|
Ritolukast (Wy-48252) is an orally active aerosol leukotriene (LTD4/E4) receptor antagonist. Ritolukast can be used to inhibit the bronchoconstriction caused by aerosol LTD4 in guinea pigs, with an ID50 of 0.5mg/kg .
|
-
-
- HY-U00359
-
-
-
- HY-168784
-
|
|
Leukotriene Receptor
|
Metabolic Disease
Inflammation/Immunology
|
|
LTD4 antagonist 2 (compound 6) is a leukotriene D4 (LTD4) antagonist with an IC50 of 2.8 μM against cysteinyl leukotriene 1 receptor (CysLT1R). LTD4 antagonist 2 is also a G protein-coupled bile acid receptor 1 (GPBAR1) agonist and can be utilized in research related to colitis, metabolic syndromes, and other GPBAR1/CysLT1R-related diseases .
|
-
-
- HY-W747563
-
|
11-trans LTD4
|
Drug Isomer
|
Others
|
|
11-trans Leukotriene D4 (11-trans LTD4) is a C-11 double bond isomer of LTD4. LTD4 undergoes slow temperature-dependent isomerization to 11-trans LTD4 during storage. 11-trans LTD4 retains about 10-25 % of the potency for contraction of guinea pig ileum, trachea and parenchyma compared to LTD4. It exhibits an ED50 ranging between 12-60 nM for contraction of guinea pig trachea.
|
-
-
- HY-N8892
-
-
-
- HY-137493
-
|
14,15-LTD4; Eoxin D4
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
14,15-Leukotriene D4 (14,15-LTD4) is a leukotriene that producted by eosinophils with Arachidonic acid (HY-109590), and through the 15-lipoxygenase-1 pathway .
|
-
-
- HY-U00072
-
-
-
- HY-113758
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
LY 163443 is a selective antagonist of leukotrienes D4 (LTD4) and E4 (LTE4). LY 163443 can antagonize LTD4-induced contractions of guinea pig ileum, trachea, and lung parenchyma. LY 163443 also inhibits tracheal contractions to LTE4 .
|
-
-
- HY-100316
-
-
-
- HY-136831
-
|
QMPB
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
SR2640 is a highly efficient and selective LTD4/LTE4 antagonist that can specifically inhibit the smooth muscle contractions induced by LTD4 in the guinea pig ileum and trachea in a concentration-dependent manner, without affecting the contractions caused by histamine. SR2640 can concentration-dependently prevent the binding of 0.4 nM [3H] LTD4 to membrane receptors in guinea pig lung tissue, with an IC50 of 23 nM. SR2640 can shift the dose-response curve for bronchoconstriction induced by intravenous LTD4 in guinea pigs to the right, and the extent of this shift is positively correlated with the dose of SR2640 administered. SR2640 can be used in asthma research .
|
-
-
- HY-101731
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
CP-96021 hydrochloride is a balanced, combined, potent and orally active leukotriene D4 (LTD4)/platelet activating factor (PAF) receptor antagonist with Ki values of 34 nM and 37 nM, respectively .
|
-
-
- HY-120755
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
LY290324 is a potent and orally active leukotriene D4 (LTD4) antagonist. LY290324 reduces LTC4, LTD4 and LTE4 (HY-113465)-induced bronchospasm. LY290324 has the potential for the research of antigen-induced bronchospasm .
|
-
-
- HY-125408
-
|
MCTR1
|
Leukotriene Receptor
|
Cardiovascular Disease
Inflammation/Immunology
|
|
Maresin conjugates in tissue regeneration 1 (MCTR1) is a potent cytokine of pro-resolving mediating maresin conjugates in tissue regeneration (MCTR), which reduces the inflammatory response and promotes tissue regeneration. Maresin conjugates in tissue regeneration 1 antagonize LTD4-stimulated vascular responses .
|
-
-
- HY-113693
-
|
|
Leukotriene Receptor
|
Others
|
|
ONO-RS-347 is an orally active and potent antagonist of leukotriene C4 and D4. ONO-RS-347 inhibits LTD4-induced bronchoconstriction in guinea pigs. ONO-RS-347 is promising for research of allergic asthma and other immediate hypersensitivty diseases .
|
-
-
- HY-105221
-
-
-
- HY-100724
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
YM-17690 is a LTD4 and LTE4 agonist, with a pKi value of 9.28 for [3H]LTD4. It induces dose-dependent contractions in guinea pig ileum, lung parenchyma, and trachea, with EC50 values of 16, 3.9, and 22 nM, respectively. YM-17690 can be used in research related to asthma and inflammation .
|
-
-
- HY-U00364
-
-
-
- HY-19041
-
-
-
- HY-122149
-
-
-
- HY-115356
-
|
14,15-LTE4; EoxE4
|
Drug Metabolite
|
Cardiovascular Disease
|
|
Eoxin E4 (14,15-LTE4) is the metabolite of 14,15-LTC4 and 14,15-LTD4. Eoxin E4 increases vascular permeability of human endothelial cell monolayers with about 10-fold less potency than LTC4, but approximately 100-fold greater potency than histamine .
|
-
-
- HY-130138A
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
(5S,6R)-DiHETE is an enantiomer of (5,6)-DiHETEs. (5S,6R)-DiHETE can be recognized by leukotriene receptors (LTD4 receptors). (5S,6R)-DiHETE can induce guinea pig isolated ileum contraction with an EC50 of 1.3 μM, and this effect can be inhibited by LTD4 receptor antagonists .
|
-
-
- HY-U00355
-
-
-
- HY-120486
-
-
-
- HY-17492
-
-
-
- HY-107611
-
-
-
- HY-107508
-
|
|
mGluR
|
Neurological Disease
|
|
VU-29 is a positive allosteric modulator of metabotropic glutamate 5 (mGlu5) receptor (EC50=9 nM and Ki=244 nM for rmGluR5). VU-29 is selective for mGluR5 relative to other mGluR subtypes (EC50: rmGluR1/rmGluR2=557 nM/1.5 μM; hmGluR4=154 nM) .
|
-
-
- HY-130138B
-
|
(5S,6R)-(11E)-DiHETE
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
(5S,6R)-DiHETEs is the isomer of (5S,6R)-DiHETE (HY-130138A). (5S,6R)-DiHETE can be recognized by leukotriene receptors (LTD4 receptors). (5S,6R)-DiHETE can induce guinea pig isolated ileum contraction with an EC50 of 1.3 μM, and this effect can be inhibited by LTD4 receptor antagonists .
|
-
-
- HY-101676
-
|
NID 525
|
Leukotriene Receptor
PPAR
Cytochrome P450
|
Metabolic Disease
|
|
RG-12525 is a a specific, competitive and orally effective antagonist of the peptidoleukotrienes, LTC4, LTD4 and LTE4, inhibiting LTC4-, LTD4- and LTE4-inducd guinea pig parenchymal strips contractions, with IC50s of 2.6 nM, 2.5 nM and 7 nM, respectively; RG-12525 is also a peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonist with IC50 of appr 60 nM and a potent inhibitor of CYP3A4, with a Ki value of 0.5 µM.
|
-
-
- HY-118958
-
|
Ro 23-3544
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
Ablukast (Ro 23-3544) is a specific and active leukotriene receptor antagonist. Ablukast effectively reduces LTC4- and antigen-induced bronchoconstriction . Ablukast is LTD4 receptor antagonist .
|
-
-
- HY-108963
-
|
|
PKC
Leukotriene Receptor
|
Cancer
|
|
LY 170198 is a protein kinase C inhibitor and a LTD4 antagonist. LY 170198 is promising for research of tumor promotion, oncogene activation, protein phosphorylation, feedback mechanisms in signal transduction and cellular responses to growth factors .
|
-
-
- HY-101946
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
AS-35 is an orally effective, potent and selective antagonist of leukotrienes, antagonizes LTC4-, LTD4 and LTE4-induced contractions of the ileum with IC50 values of 8 nM, 4 nM and 3 nM, respectively, and has antiallergic activities.
|
-
-
- HY-17492S
-
-
-
- HY-164650
-
|
Sch 37224
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
Pirodomast (Sch 37224) is a leukotriene formation inhibitor. Pirodomast inhibits LTD4 andthromboxane B2 release by anaphylactic guinea pig lung with the IC50 values of 3.9 and 1.9 μM, respectively. Pirodomast can be used for study of asthma .
|
-
-
- HY-17492S3
-
-
-
- HY-17492R
-
|
ICI 204219 (Standard)
|
Reference Standards
Leukotriene Receptor
|
Inflammation/Immunology
Cancer
|
|
Zafirlukast (Standard) is the analytical standard of Zafirlukast. This product is intended for research and analytical applications. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
|
-
-
- HY-17492S2
-
-
-
- HY-17492S1
-
-
-
- HY-113465
-
|
LTE4
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.
|
-
-
- HY-163101
-
|
|
Platelet-activating Factor Receptor (PAFR)
Leukotriene Receptor
|
Inflammation/Immunology
|
|
CP-96021 is a potent and orally available leukotriene D4 (LTD4 Ki=34 μM) / platelet activating factor (PAF Ki=37 μM) receptor antagonist. CP-96021 has antagonist capable of simultaneously targeting two different inflammatory mediators, LTD4 and PAF. CP-96021 shows high specificity for α1, α2, β, dopamine-2, adenosine 1, 5-HT1, H1, muscarine, μ opioid, and GABA receptors, all expressing IC50 values greater than 10 μM. CP-96021 can be used to study the pathogenesis of many inflammatory diseases such as asthma .
|
-
-
- HY-P4106A
-
|
|
Amino Acid Derivatives
|
Neurological Disease
|
|
Tat-GluR23Y, scrambled TFA is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .
|
-
-
- HY-P4106
-
|
|
Amino Acid Derivatives
|
Neurological Disease
|
|
Tat-GluR23Y, scrambled is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .
|
-
-
- HY-117842
-
|
|
Histamine Receptor
|
Inflammation/Immunology
|
|
KY 234 is an orally effective inhibitor that targets thromboxane A2 production, with an IC50 of 5 μM. KY 234 significantly inhibits leukotriene D4 (LTD4), histamine, and antigen-induced bronchoconstriction in guinea pigs, with IC50 values of 6.0 mg/kg, 2.5 mg/kg, and 6.3 mg/kg, respectively .
|
-
-
- HY-B0290
-
-
-
- HY-B0290A
-
|
ONO-1078 hemihydrate
|
Leukotriene Receptor
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [ 3H]LTE4, [ 3H]LTD4, and [ 3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
|
-
-
- HY-113465S
-
|
LTE4-d5
|
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Leukotriene E4-d5 is the deuterium labeled Leukotriene E4. Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.
|
-
-
- HY-B0290S1
-
-
-
- HY-B0290R
-
|
ONO-1078 (Standard)
|
Reference Standards
Leukotriene Receptor
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Pranlukast (Standard) is the analytical standard of Pranlukast. This product is intended for research and analytical applications. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [ 3H]LTE4, [ 3H]LTD4, and [ 3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
|
-
-
- HY-19042
-
|
YM 638
|
Leukotriene Receptor
|
Inflammation/Immunology
|
YM-16638 is an orally active leukotriene (LT) antagonist. YM-16638 can inhibit the production of LTC4, LTD4, and LTE4 in guinea pig trachea, with IC50 values of 0.05 μM, 0.16 μM, and 0.096 μM, respectively. YM-16638 has a dose-dependent inhibitory effect on antigen-induced early and late respiratory responses in allergic sheep .
|
-
-
- HY-B0290AR
-
|
|
Leukotriene Receptor
Endogenous Metabolite
|
Inflammation/Immunology
|
|
Pranlukast (hemihydrate) (Standard) is the analytical standard of Pranlukast (hemihydrate). This product is intended for research and analytical applications. Pranlukast hemihydrate is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
|
-
- HY-19989
-
|
L-660711
|
P-glycoprotein
LPL Receptor
Leukotriene Receptor
|
Inflammation/Immunology
|
|
MK-571 (L-660711) is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 is also a MRP4 and ABCC1 (MRP1) inhibitor. MK-571 inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .
|
-
- HY-19989A
-
|
L-660711 sodium
|
P-glycoprotein
LPL Receptor
Leukotriene Receptor
|
Inflammation/Immunology
|
|
MK-571 (L-660711) sodium is an orally active, potent and selective competitive leukotriene D4 (LTD4) receptor antagonist, with Ki values of 0.22 and 2.1 nM in guinea pig and human lung membranes, respectively. MK-571 sodium is also a inhibitor of multidrug resistance-associated protein MRP4 (ABCC4) and ABCC1 (MRP1). MK-571 sodium inhibits constitutive and antigen-stimulated S1P (sphingosine-1-phosphate) release .
|
-
- HY-B0764B
-
|
Dibutyryl cAMP; DBcAMP
|
PKA
|
Neurological Disease
|
|
Bucladesine (DBcAMP) is a membrane permeable selective activator that activates cyclic adenosine phosphate dependent protein kinase A (PKA). The main regulatory mechanism of Bucladesine involves the cAMP/PKA signaling pathway. When Bucladesine activates PKA, it can promote a variety of cellular processes, including neurodevelopment, growth and plasticity. In particular, the cAMP/PKA signaling pathway plays a key role in the expression of long-term enhancement (LTP) and long-term inhibition (LTD), as well as in the formation of long-term memory in the hippocampus. Bucladesine can be used to study memory formation and neuroplasticity .
|
-
- HY-117854
-
|
|
Leukotriene Receptor
|
Inflammation/Immunology
|
|
SB 201146 is an LTB4 receptor antagonist with a potency range of 10 pM to 1 μM that plays a critical role in asthma-associated airway inflammation. Studies have focused on its effects on eosinophil survival, a hallmark of asthma pathology. Studies have shown that eosinophil-derived cysteinyl leukotrienes, including LTC4 and LTD4, as well as factors such as GM-CSF and fibronectin promote eosinophil survival. SB 201146 effectively reversed mast cell- and lymphocyte-induced eosinophil survival, highlighting its potential therapeutic role in disrupting the autocrine cysteinyl leukotriene pathway that maintains eosinophil viability. This antagonist also highlights the importance of LTB4 as a paracrine mediator that influences eosinophil survival in inflammatory settings such as asthma .
|
-
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P2259
-
|
|
iGluR
|
Neurological Disease
|
|
TAT-GluA2 3Y, an interference peptide, blocks long-term depression (LTD) at glutamatergic synapses by disrupting the endocytosis of AMPAR. TAT-GluA2 3Y can alleviate Pentobarbital-induced spatial memory deficits and synaptic depression .
|
-
- HY-P4106A
-
|
|
Amino Acid Derivatives
|
Neurological Disease
|
|
Tat-GluR23Y, scrambled TFA is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .
|
-
- HY-P4106
-
|
|
Amino Acid Derivatives
|
Neurological Disease
|
|
Tat-GluR23Y, scrambled is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD) .
|
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-17492S
-
|
|
|
Zafirlukast-d7 is the deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects .
|
-
-
- HY-17492S3
-
|
|
|
Zafirlukast-d6 is deuterated labeled Zafirlukast (HY-17492). Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
|
-
-
- HY-17492S2
-
|
|
|
Zafirlukast- 13C,d6 is the 13C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
|
-
-
- HY-17492S1
-
|
|
|
Zafirlukast- 13C,d3 is the 13C- and deuterium labeled Zafirlukast. Zafirlukast (ICI 204219) is a potent orally active leukotriene D4 (LTD4) receptor antagonist. Zafirlukast shows anti-asthmatic, anti-inflammatory and anti-bacterial effects.
|
-
-
- HY-113465S
-
|
|
|
Leukotriene E4-d5 is the deuterium labeled Leukotriene E4. Leukotriene E4 (LTE4) is produced by the action of dipeptidase on LTD4. Leukotriene E4 is one of the constituents of slow-reacting substance of anaphylaxis (SRS-A). Leukotriene E4 accumulates in both plasma and urine and urinary excretion of Leukotriene E4 is most often used as an indicator of asthma.
|
-
-
- HY-B0290S1
-
|
|
|
Pranlukast-d4 is deuterium labeled Pranlukast. Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.
|
-
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
